Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial

The Lancet Oncology - Tập 15 - Trang 1389-1396 - 2014
Sung Hoon Noh1, Sook Ryun Park2, Han-Kwang Yang3, Hyun Cheol Chung4, Ik-Joo Chung5, Sang-Woon Kim6, Hyung-Ho Kim7, Jin-Hyuk Choi8, Hoon-Kyo Kim9, Wansik Yu10, Jong Inn Lee11, Dong Bok Shin12, Jiafu Ji13, Jen-Shi Chen14, Yunni Lim15, Stella Ha15, Yung-Jue Bang16
1Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea
2Gastric Cancer Branch, Research Institute and Hospital, National Cancer Center, Goyang, South Korea
3Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea
4Department of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea
5Department of Internal Medicine, Chonnam National University Hwasun Hospital, Jeonnam, South Korea
6Department of Surgery, Yeungnam University College of Medicine, Daegu, South Korea
7Department of Surgery, Seoul National University Bundang Hospital, Seongnam, South Korea
8Department of Hematology-Oncology, Ajou University Hospital, Suwon, South Korea
9Department of Internal Medicine, St. Vincent's Hospital, Suwon, South Korea
10Department of Surgery, Kyungpook National University Medical Center, Daegu, South Korea
11Department of Surgery, Korea Institute of Radiological and Medical Sciences, Korea Cancer Center, Seoul, South Korea
12Department of Hematology-Oncology, Gachon University Gil Medical Center, Incheon, South Korea
13Beijing Cancer Hospital, Beijing, China
14Department of Internal Medicine, Chang Gung Memorial Hospital and Chang Gung University Taipei, Taoyuan, Taiwan
15Clinical Research Division, Roche Korea, Seoul, South Korea
16Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea

Tài liệu tham khảo

Kodera, 1988, The number of metastatic lymph nodes: a promising prognostic determinant for gastric carcinoma in the latest edition of the TNM classification, J Am Coll Surg, 187, 597, 10.1016/S1072-7515(98)00229-4 Adachi, 1994, Prognostic significance of the number of positive lymph nodes in gastric carcinoma, Br J Surg, 81, 414, 10.1002/bjs.1800810331 Sasako, 2010, Gastric Cancer Working Group report, Jpn J Clin Oncol, 40, I28, 10.1093/jjco/hyq124 Okines, 2010, Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 21, V50, 10.1093/annonc/mdq164 Allum, 2011, Guidelines for the management of oesophageal and gastric cancer, Gut, 60, 1449, 10.1136/gut.2010.228254 Van Cutsem, 2011, The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010, Ann Oncol, 22, V1, 10.1093/annonc/mdr284 Songun, 2010, Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial, Lancet Oncol, 11, 439, 10.1016/S1470-2045(10)70070-X Wu, 2006, Nodal dissection for patients with gastric cancer: a randomised controlled trial, Lancet Oncol, 7, 309, 10.1016/S1470-2045(06)70623-4 D'Angelica, 2004, Patterns of initial recurrence in completely resected gastric adenocarcinoma, Ann Surg, 240, 808, 10.1097/01.sla.0000143245.28656.15 Wu, 2003, Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer, World J Surg, 27, 153, 10.1007/s00268-002-6279-7 Macdonald, 2001, Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction, N Engl J Med, 345, 725, 10.1056/NEJMoa010187 Cunningham, 2006, Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer, N Engl J Med, 355, 11, 10.1056/NEJMoa055531 Sakuramoto, 2007, Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine, N Engl J Med, 357, 1810, 10.1056/NEJMoa072252 Bang, 2012, Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial, Lancet, 379, 315, 10.1016/S0140-6736(11)61873-4 Sasako, 2011, Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer, J Clin Oncol, 29, 4387, 10.1200/JCO.2011.36.5908 2003 Paoletti, 2010, Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis, JAMA, 303, 1729, 10.1001/jama.2010.534 Bajetta, 2014, Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer, Ann Oncol, 25, 1373, 10.1093/annonc/mdu146 Zhu, 2012, A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection, Radiother Oncol, 104, 361, 10.1016/j.radonc.2012.08.024 Lee, 2012, Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial, J Clin Oncol, 30, 268, 10.1200/JCO.2011.39.1953 Cassidy, 2008, Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer, J Clin Oncol, 26, 2006, 10.1200/JCO.2007.14.9898 Haller, 2011, Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer, J Clin Oncol, 29, 1465, 10.1200/JCO.2010.33.6297
Thông tin
Thông tin xuất bản

The Lancet Oncology

Tập 15

1389-1396

Thông tin tác giả